REAL SCIENCE. REAL POSSIBILITIES.One of the most studied NAD+ precursors, NR is the focus of human research into cellular energy, metabolism and healthy ageing.
NR is one of the better-studied ways of supporting NAD+ levels and attracts interest around energy, metabolism and healthy ageing, with considerably more human research than many experimental compounds.
These cards show what NR is best known for and where the interest comes from. When you want the detail, open Research for the studies or Evidence for a quick view of how strong the support is.
The main reasons this compound attracts attention. The Research and Evidence sections give you the deeper scientific picture.
The most consistent finding with NR is that taking it can raise NAD-related markers in the body.
Multiple human trials have demonstrated increases in NAD-related biomarkers after oral NR.
Researchers have looked at whether those NAD+ changes translate into improvements in blood pressure, insulin sensitivity and other metabolic measures.
Results are mixed: some studies show encouraging signals while others find little or no meaningful change, depending on the population and outcome measured.
NR is also explored for maintaining muscle function, energy and the health of the mitochondria that help power our cells.
Changes in NAD-related biology are clearer than consistent improvements in strength, endurance or everyday physical function.
Like NMN, much of the wider interest in NR comes from the idea of supporting NAD+ as levels and metabolism change with age.
Human research has not yet shown that NR produces a broad anti-ageing effect or extends lifespan.
NR is one of the better-studied ways of supporting NAD+ levels and attracts interest around energy, metabolism and healthy ageing, with considerably more human research than many experimental compounds.
Multiple human trials have demonstrated increases in NAD-related biomarkers after oral NR.
Results are mixed: some studies show encouraging signals while others find little or no meaningful change, depending on the population and outcome measured.
Changes in NAD-related biology are clearer than consistent improvements in strength, endurance or everyday physical function.
Human research has not yet shown that NR produces a broad anti-ageing effect or extends lifespan.
24 healthy middle-aged and older adults
This score reflects completed human outcome evidence. A registered or recruiting trial does not count until results are reported.
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
Recurring themes from peptide and wellness communities, shown alongside what published research currently suggests.
NR is explored as a practical way to raise NAD-related metabolites, particularly for energy, metabolic health and ageing. It has a useful human evidence base, but stronger biomarker results than day-to-day outcome results.
Experiences can reveal recurring goals, perceived changes and practical questions that formal studies may not yet address. They can suggest what deserves investigation, but cannot isolate the effect of one compound from rehabilitation, time or other changes.
Human and preclinical research helps test whether an idea is biologically plausible, whether it appears in people and how confidently the result can be separated from chance, bias or other parts of recovery.
Randomized human studies consistently show increases in blood NAD-related metabolites after oral NR.
NR feeds into the NAD salvage pathway and has strong mechanistic support.
Target engagement is well supported; clinical benefit still needs to be judged separately.
Changes in NAD biology have not consistently produced meaningful improvements in strength, endurance or everyday energy.
Mitochondrial biology provides a rationale but does not guarantee a perceptible effect.
A plausible goal with inconsistent human outcome evidence.
Trials explore vascular, metabolic and muscle outcomes, but do not demonstrate slower ageing or longer life.
Age-related changes in NAD biology drive the hypothesis.
An active field rather than an established anti-ageing treatment.
Community reports can surface patterns worth exploring. Controlled human research is what tests whether those patterns are reliable, clinically meaningful and attributable toNR, while the available studies show how far that question has already been answered.
Compare published study protocols with the patterns people discuss in the community. The two are intentionally kept separate so an anecdotal routine is never mistaken for clinical guidance.
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NR has multiple human supplementation studies, but trial doses and outcomes differ by population and should not be converted into a universal clinical regimen.
Healthy adults aged 55–79
Published study structure, shown as data — not a personal dosing schedule.
Research protocol used to examine tolerability and NAD+ metabolism; not a general dosing recommendation.
250–300 mg once daily is a common lower starting range in supplement discussions.
500–1,000 mg per day has appeared in human research and community use, often reviewed after six-to-twelve weeks.
Longer-term daily use is common, but no universal evidence-based maintenance dose or cycling schedule has been established.
The summary above reflects the human or preclinical evidence currently represented on this profile.
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
NR, NMN, NADH and direct NAD+ are related but distinct. Doses and outcomes should not be transferred between them as though they were interchangeable.
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
Oral NR reliably changes NAD-related biomarkers. A broad anti-ageing or disease-treatment claim has not been established.
Nature Communications trial ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.